Prothrombin Activation Is Increased among Asymptomatic Carriers of the Prothrombin G20210A and Factor V Arg506Gln Mutations

Summary The risk of venous thrombosis is increased in individuals who carry specific genetic abnormalities in blood coagulation proteins. Among Caucasians, the prothrombin G20210A and factor V Arg506Gln (FV R506Q) mutations are the most prevalent defects identified to date. We evaluated their influence on markers of coagulation activation among participants in the Second Northwick Park Heart Study, which recruited healthy men (aged 50–61 years) from nine general medical practices in England and Wales. They were free of clinical vascular disease and malignancy at the time of recruitment. Genotypes for the two mutations were analyzed using microplate array diagonal gel electrophoresis, and coagulation markers (factor XIIa; activation peptides of factor IX, factor X, and prothrombin; fibrinopeptide A) were measured by immunoassay. Factor VII coagulant activity and factor VIIa levels were determined by a functional clotting assay. Among 1548 men genotyped for both mutations, 28 (1.8%) and 52 (3.4%) were heterozygous for prothrombin G20210A and FV R506Q, respectively. The only coagulation marker that was significantly associated with the two mutations was prothrombin activation fragment F1+2 [mean ± SD, 0.88 ± 0.32 nmol/L in men with prothrombin G20210A (p = 0.002) and 0.89 ± 0.30 in men with FV R506Q (p = 0.0001) versus 0.72 ± 0.24 among non-carriers for either mutation]. This data provides conclusive evidence that heterozygosity for the prothrombin G20210A as well as the FV R506Q mutations in the general population leads to an increased rate of prothrombin activation in vivo.

[1]  K. Mann,et al.  "Normal" thrombin generation. , 1999, Blood.

[2]  M. Woodward,et al.  Activated Protein C Resistance and the FV:R506Q Mutation in a Random Population Sample , 1999, Thrombosis and Haemostasis.

[3]  S. Béguin,et al.  Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[4]  P. Reitsma,et al.  Geographic Distribution of the 20210 G to A Prothrombin Variant , 1998, Thrombosis and Haemostasis.

[5]  J. Cooper,et al.  Activation of the Coagulant Pathway in Cigarette Smokers , 1998, Thrombosis and Haemostasis.

[6]  J. Corral,et al.  The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease , 1997, British journal of haematology.

[7]  F R Rosendaal,et al.  A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. , 1997, Blood.

[8]  K. Mann,et al.  Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN * , 1997, The Journal of Biological Chemistry.

[9]  T. Raghunathan,et al.  Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. , 1997, Blood.

[10]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[11]  D. Ardissino,et al.  Factor V (Arg506⟶ Gln) Mutation in Young Survivors of Myocardial Infarction , 1996, Thrombosis and Haemostasis.

[12]  R. Ford,et al.  An enzyme-linked immunosorbent assay (ELISA) for the measurement of activated factor XII (Hageman factor) in human plasma. , 1996, Journal of immunoassay.

[13]  P. Mannucci,et al.  Heightened Thrombin Generation in Individuals with Resistance to Activated Protein C , 1996, Thrombosis and Haemostasis.

[14]  B. Dahlbäck,et al.  Elevated Levels of Prothrombin Activation Fragment 1+2 in Plasma from Patients with Heterozygous Arg506 to Gin Mutation in the Factor V Gene (APC-Resistance) and/or Inherited Protein S Deficiency , 1996, Thrombosis and Haemostasis.

[15]  P. Simioni,et al.  Prothrombin fragment 1+2 and thrombin–antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation , 1996, British journal of haematology.

[16]  S. Humphries,et al.  High-throughput genotyping using horizontal polyacrylamide gels with wells arranged for microplate array diagonal gel electrophoresis (MADGE). , 1995, BioTechniques.

[17]  J. Griffin,et al.  Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. , 1995, Blood.

[18]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[19]  K. Mann,et al.  Characterization of the Molecular Defect in Factor VR506A(*) , 1995, The Journal of Biological Chemistry.

[20]  A. Schafer.  Hypercoagulable states: molecular genetics to clinical practice , 1994, The Lancet.

[21]  B. Dahlbäck,et al.  Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. , 1994, The Journal of clinical investigation.

[22]  S. Humphries,et al.  Electrophoresis for genotyping: microtiter array diagonal gel electrophoresis on horizontal polyacrylamide gels, hydrolink, or agarose. , 1994, Analytical biochemistry.

[23]  J. Voorberg,et al.  Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V , 1994, The Lancet.

[24]  B. Evatt,et al.  Activated protein C resistance caused by Arg506Gln mutation in factor Va , 1994, The Lancet.

[25]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[26]  J. Miletich,et al.  Inherited predisposition to thrombosis , 1993, Cell.

[27]  P. Mannucci,et al.  Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes , 1992, Thrombosis and Haemostasis.

[28]  W. Stüber,et al.  Determination of Human Prothrombin Activation Fragment 1+2 in Plasma with an Antibody against a Synthetic Peptide , 1991, Thrombosis and Haemostasis.

[29]  H. ten Cate,et al.  Factor IX is activated in vivo by the tissue factor mechanism. , 1990, Blood.

[30]  M. Bednarek,et al.  DETECTION OF FACTOR X ACTIVATION IN HUMANS , 1989, Thrombosis and Haemostasis.

[31]  R. Bertina,et al.  Hemostatic enzyme generation in the blood of patients with hereditary protein C deficiency. , 1988, Blood.

[32]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[33]  K. Bauer,et al.  Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex. , 1982, Blood.

[34]  F R Rosendaal,et al.  Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .

[35]  J. Miletich.  Thrombophilia as a multigenic disorder. , 1998, Seminars in thrombosis and hemostasis.

[36]  D. Ardissino,et al.  Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. , 1996, Thrombosis and haemostasis.

[37]  J. Cooper,et al.  The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.

[38]  G. Miller,et al.  Factor VII-Deficient Substrate Plasmas Depleted of Protein C Raise the Sensitivity of the Factor VII Bio-Assay to Activated Factor VII: an International Study , 1994, Thrombosis and Haemostasis.

[39]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. , 1993, Blood.

[40]  J. Griffin,et al.  Normalization of markers of coagulation activation with a purified protein C concentrate in adults with homozygous protein C deficiency. , 1993, Blood.